Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Industry, Sector and Symbol:

Sector: Medical
Industry: Pharmaceuticals
Sub-Industry: N/A
Symbol: NASDAQ:COLL
CUSIP: N/A
Web: www.collegiumpharma.com

Capitalization:

Market Cap: $332.62 million
Outstanding Shares: 29,566,000

Average Prices:

50 Day Moving Avg: $10.76
200 Day Moving Avg: $10.76
52 Week Range: $7.37 - $18.67

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -5.98
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $7.44 million
Price / Sales: 44.71
Book Value: $3.23 per share
Price / Book: 3.48

Profitability:

EBITDA: ($97,950,000.00)
Net Margins: -1,319.39%
Return on Equity: -93.73%
Return on Assets: -74.81%

Debt:

Current Ratio: 4.22%
Quick Ratio: 4.17%

Misc:

Average Volume: 615,152 shs.
Beta: -0.11
Short Ratio: 20.34

Frequently Asked Questions for Collegium Pharmaceutical (NASDAQ:COLL)

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million for the quarter, compared to analysts' expectations of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. View Collegium Pharmaceutical's Earnings History.

When will Collegium Pharmaceutical make its next earnings announcement?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Collegium Pharmaceutical.

Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2017?

5 brokerages have issued 12-month target prices for Collegium Pharmaceutical's shares. Their predictions range from $14.00 to $25.00. On average, they expect Collegium Pharmaceutical's share price to reach $20.00 in the next year. View Analyst Ratings for Collegium Pharmaceutical.

Who are some of Collegium Pharmaceutical's key competitors?

Some companies that are related to Collegium Pharmaceutical include AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Corium International (CORI), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals Corporation (ADMP), Marinus Pharmaceuticals (MRNS), Aralez Pharmaceuticals (ARLZ), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Evoke Pharma (EVOK), SCYNEXIS (SCYX) and Concordia International Corp. (CXRX).

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:

Michael Thomas Heffernan, Chairman of the Board, President, Chief Executive Officer
Paul Brannelly CPA, Chief Financial Officer, Executive Vice President
Joseph J. Ciaffoni, Chief Operating Officer, Executive Vice President
Douglas R. Carlson, Vice President - Corporate Development
Alison B Fleming, Vice President of Product Development
Ernest A. Kopecky Ph.D., Vice President - Clinical Development and Head of Neuroscience
Kevin OKeeffe, Vice President - Market Access and Trade
Steven Passik Ph.D., Vice President - Scientific Affairs, Education and Policy
Said Saim Ph.D., Vice President of Pharmaceutical Development
John Weet Ph.D., Vice President - Regulatory Affairs and Quality Assurance

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

How do I buy Collegium Pharmaceutical stock?

Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of Collegium Pharmaceutical stock can currently be purchased for approximately $11.25.

MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		108 (Vote Outperform)
Underperform Votes:		127 (Vote Underperform)
Total Votes:		235

MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Collegium Pharmaceutical (NASDAQ:COLL) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	5 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$20.00 (77.78% upside)

Consensus Price Target History for Collegium Pharmaceutical (NASDAQ:COLL)

Analysts' Ratings History for Collegium Pharmaceutical (NASDAQ:COLL)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/6/2017	Needham & Company LLC	Reiterated Rating	Buy	$25.00	N/A
10/6/2017	Jefferies Group LLC	Reiterated Rating	Buy	$15.00	N/A
9/11/2017	HC Wainwright	Initiated Coverage	Buy -> Buy	$21.00	High
9/8/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$14.00	Low
6/12/2017	Janney Montgomery Scott	Reiterated Rating	Buy	$25.00	Medium
9/13/2016	Gabelli	Initiated Coverage	Buy	$25.00	N/A
2/19/2016	William Blair	Initiated Coverage	Outperform	$35.00	N/A

(Data available from 10/16/2015 forward)

Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)

Earnings by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Earnings History by Quarter for Collegium Pharmaceutical (NASDAQ COLL)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/8/2017		($0.75)					N/A
8/9/2017	Q2 2017	($0.81)	($0.72)	$4.07 million	$3.56 million	View	Listen
5/10/2017	Q1 2017	($0.98)	($0.79)	$3.55 million	$2.17 million	View	N/A
3/9/2017	Q4 2016	($1.07)	($1.02)	$1.79 million	$1.30 million	View	Listen
11/10/2016	Q3 2016	($1.09)	($1.13)	$1.00 million	$0.41 million	View	Listen
8/10/2016	Q2	($0.76)	($1.05)	$0.16 million		View	Listen
5/10/2016	Q1	($0.60)	($0.68)			View	Listen
3/15/2016	Q415	($0.45)	($0.46)			View	Listen
11/12/2015	Q315	($0.30)	($0.46)			View	Listen
8/12/2015	Q215	($0.26)	($0.45)			View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

2017 EPS Consensus Estimate: ($3.22)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.89)	($0.89)	($0.89)
Q2 2017	2	($0.81)	($0.76)	($0.79)
Q3 2017	2	($0.81)	($0.67)	($0.74)
Q4 2017	2	($1.00)	($0.61)	($0.81)

(Data provided by Zacks Investment Research)

Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Collegium Pharmaceutical (NASDAQ:COLL)

Insider Ownership Percentage: 25.76%
Institutional Ownership Percentage: 83.04%

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/12/2017	Paul Brannelly	Insider	Buy	10,000	$9.18	$91,800.00
8/12/2016	John A Fallon	Director	Buy	2,375	$10.59	$25,151.25
5/12/2015	John Gordon Freund	Director	Buy	150,000	$12.00	$1,800,000.00
5/12/2015	Longitude Capital Partners, Ll	Major Shareholder	Buy	200,000	$12.00	$2,400,000.00

(Data available from 1/1/2013 forward)

Headline Trends for Collegium Pharmaceutical (NASDAQ:COLL) Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)

Source:

Date	Headline
	Brokerages Anticipate Collegium Pharmaceutical, Inc. (COLL) to Post -$0.74 EPS www.americanbankingnews.com - October 16 at 8:20 AM
	Collegium Pharmaceutical, Inc. (COLL) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - October 15 at 9:28 AM
	Analyzing Collegium Pharmaceutical (COLL) and Its Rivals www.americanbankingnews.com - October 14 at 10:22 PM
	Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session finance.yahoo.com - October 6 at 5:40 PM
	Jefferies Group LLC Reiterates Buy Rating for Collegium Pharmaceutical, Inc. (COLL) www.americanbankingnews.com - October 6 at 9:36 AM
	Needham & Company LLC Reaffirms "Buy" Rating for Collegium Pharmaceutical, Inc. (COLL) www.americanbankingnews.com - October 6 at 9:36 AM
	Pre-Market Most Active for Oct 5, 2017 : LYG, MTDR, TROX, RIGL, CDNA, COLL, ECYT, INO, CATB, TEVA, SHOP, MFGP - Nasdaq www.nasdaq.com - October 5 at 4:31 PM
	Cigna to end OxyContin painkiller coverage, signs contract for alternative finance.yahoo.com - October 5 at 11:06 AM
	Collegium Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : COLL-US : October 3, 2017 finance.yahoo.com - October 3 at 5:18 PM
	Collegium Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : COLL-US : October 3, 2017 finance.yahoo.com - October 3 at 5:17 PM
	Collegium Pharmaceutical, Inc. (COLL) Receives "Buy" Rating from Jefferies Group LLC www.americanbankingnews.com - September 22 at 12:38 AM
	Collegium Pharmaceutical, Inc. (COLL) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - September 20 at 9:24 AM
	Benzinga's Top Upgrades, Downgrades For September 11, 2017 - Benzinga www.benzinga.com - September 11 at 6:04 PM
	Collegium Pharmaceutical's (COLL) Buy Rating Reiterated at Piper Jaffray Companies www.americanbankingnews.com - September 9 at 3:06 PM
	Collegium to Present at Upcoming Investor Conferences - GlobeNewswire (press release) globenewswire.com - September 6 at 5:23 PM
	Collegium Announces Scientific Presentations at PAINWeek 2017 Meeting - GlobeNewswire (press release) globenewswire.com - September 5 at 11:57 PM
	Collegium Pharmaceutical, Inc. (COLL) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - August 26 at 9:26 AM
	BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End - Nasdaq www.nasdaq.com - August 24 at 10:39 PM
	$5.03 Million in Sales Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter www.americanbankingnews.com - August 23 at 11:32 AM
	Collegium Pharmaceutical, Inc. – Value Analysis (NASDAQ:COLL) : August 17, 2017 finance.yahoo.com - August 16 at 10:51 PM
	FY2017 Earnings Estimate for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Issued By Gabelli www.americanbankingnews.com - August 14 at 5:52 AM
	Jefferies Group Weighs in on Collegium Pharmaceutical, Inc.'s Q3 2017 Earnings (COLL) www.americanbankingnews.com - August 14 at 3:18 AM
	William Blair Comments on Collegium Pharmaceutical, Inc.'s Q3 2017 Earnings (COLL) www.americanbankingnews.com - August 14 at 3:18 AM
	FY2020 EPS Estimates for Collegium Pharmaceutical, Inc. Lifted by Gabelli (NASDAQ:COLL) www.americanbankingnews.com - August 11 at 5:22 PM
	Edited Transcript of COLL earnings conference call or presentation 9-Aug-17 8:30pm GMT finance.yahoo.com - August 10 at 11:40 PM
	Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS www.americanbankingnews.com - August 10 at 11:04 PM
	Collegium Reports Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire (press release) globenewswire.com - August 9 at 5:37 PM
	Collegium Reports Second Quarter Financial Results and Provides Corporate Update finance.yahoo.com - August 9 at 5:37 PM
	Collegium Pharmaceutical posts 2Q loss finance.yahoo.com - August 9 at 5:37 PM
	Collegium Pharmaceutical, Inc. (COLL) Expected to Announce Quarterly Sales of $4.07 Million www.americanbankingnews.com - August 5 at 9:34 AM
	Collegium Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : COLL-US : August 4, 2017 finance.yahoo.com - August 4 at 5:37 PM
	Financial Survey: Collegium Pharmaceutical (NASDAQ:COLL) and Akorn (AKRX) www.americanbankingnews.com - August 4 at 2:26 PM
	-$0.81 EPS Expected for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) This Quarter www.americanbankingnews.com - August 3 at 7:26 AM
	Collegium Pharmaceutical, Inc. (COLL) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - August 1 at 8:53 AM
	Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - August 1 at 7:16 AM
	Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given a $14.00 Price Target at Piper Jaffray Companies www.americanbankingnews.com - July 26 at 11:59 PM
	Collegium Pharmaceutical, Inc. Expected to Post Q2 2017 Earnings of ($0.76) Per Share (COLL) www.americanbankingnews.com - July 20 at 8:12 AM
	Nektar's NKTR-181 Positive in Human Abuse Potential Study - Nasdaq www.nasdaq.com - July 19 at 6:33 PM
	Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update - Nasdaq www.nasdaq.com - July 18 at 11:53 PM
	Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update - GlobeNewswire (press release) globenewswire.com - July 18 at 6:52 PM
	Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update feeds.benzinga.com - July 18 at 4:34 PM
	Collegium Pharmaceutical Inc (COLL) Expected to Announce Quarterly Sales of $4.33 Million www.americanbankingnews.com - July 13 at 10:48 AM
	Edited Transcript of COLL earnings conference call or presentation 10-May-17 8:30pm GMT finance.yahoo.com - July 11 at 11:32 PM
	-$0.80 EPS Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter www.americanbankingnews.com - July 11 at 8:24 PM
	Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - July 7 at 10:52 AM
	Why Endo's Bad News Sent Collegium Pharmaceutical Shares Soaring 10% - Motley Fool www.fool.com - June 11 at 9:32 PM
	Collegium Announces Scientific Presentations at the 2017 ... - GlobeNewswire (press release) globenewswire.com - June 10 at 9:38 PM
	Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids - GlobeNewswire (press release) globenewswire.com - June 9 at 5:00 PM
	Collegium's stock jumps on belief its opioid drug will get a boost from a rival's woes - MarketWatch www.marketwatch.com - June 9 at 5:00 PM
	Collegium Pharma (COLL) Secures Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients www.streetinsider.com - June 1 at 5:02 PM